These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 6867995)

  • 21. Pharmacokinetic analysis of intravenously and orally administered quinidine in cows.
    McGuirk SM; Muir WW; Sams RA
    Am J Vet Res; 1981 Sep; 42(9):1482-7. PubMed ID: 7325456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enterogastric cycle and intoxication with hydroquinidine: a case report.
    Lesne M; Devos DM; Reynaert M
    Clin Toxicol; 1981 Jun; 18(6):659-62. PubMed ID: 7273674
    [No Abstract]   [Full Text] [Related]  

  • 23. The bioavailability and kinetics of dihydroquinidine in patients with heart disease.
    Regazzi Bonora M; Salerno JA; Rondanelli R; Cristiani D; Chimienti M
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):212-8. PubMed ID: 7095920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine.
    Laganière S; Davies RF; Carignan G; Foris K; Goernert L; Carrier K; Pereira C; McGilveray I
    Clin Pharmacol Ther; 1996 Sep; 60(3):255-64. PubMed ID: 8841148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
    Kharasch ED; Hoffer C; Whittington D; Sheffels P
    Clin Pharmacol Ther; 2003 Dec; 74(6):543-54. PubMed ID: 14663457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of oral neomycin on the absorption of isoniazid, quinidine and sulphafurazole from the rat small intestine in situ.
    Venho VM; Koivuniemi A
    Arzneimittelforschung; 1982; 32(2):141-3. PubMed ID: 7199917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Interaction of digoxin and quinidine].
    Haustein KO; Oltmanns G
    Z Gesamte Inn Med; 1980 Feb; 35(4):186-7. PubMed ID: 7405308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic analysis of intravenously and orally administered quinidine in horses.
    McGuirk SM; Muir WW; Sams RA
    Am J Vet Res; 1981 Jun; 42(6):938-42. PubMed ID: 7283244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate.
    Taggart WV; Holyoak W
    Clin Ther; 1983; 5(4):357-64. PubMed ID: 6871920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diurnal oscillations in the serum and salivary levels of quinidine.
    Rao BR; Rambhau D
    Arzneimittelforschung; 1995 Jun; 45(6):681-3. PubMed ID: 7646570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic interactions of nifedipine and quinidine.
    Hippius M; Henschel L; Sigusch H; Tepper J; Brendel E; Hoffmann A
    Pharmazie; 1995 Sep; 50(9):613-6. PubMed ID: 7480098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Availability and use of parenteral quinidine gluconate for severe or complicated malaria.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2000 Dec; 49(50):1138-40. PubMed ID: 11190119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Relative bioavailability of various quinidine preparations in man after a single oral dose].
    Terhaag B; Gieszinger U
    Pharmazie; 1982 Dec; 37(12):848-50. PubMed ID: 7163373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A simple method for estimating half-life of drugs obeying Michaelis-Menten elimination kinetics].
    Ding Y; Huang DK; Luo JP
    Zhongguo Yao Li Xue Bao; 1995 Jan; 16(1):65-7. PubMed ID: 7771200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Half-life time or clearance of indocyanine green in patients with liver disease.
    Gilmore IT; Marigold JH; Thompson RP
    Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tuberculosis therapy and enzyme induction in man.
    Larousse C; Le Normand Y; Kergueris MF; Veyrac MJ; Chailleux E; Ordronneau J; Moigneteau C
    Int J Clin Pharmacol Ther Toxicol; 1980 Apr; 18(4):163-8. PubMed ID: 7380590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Elimination half-life of 3-hydroxyquinidine in man].
    Camsonne R; Moulin MA; Bazin C; Charbonneau P; Drieu L; Pedailles S; Briand A
    Therapie; 1983; 38(1):115-6. PubMed ID: 6867995
    [No Abstract]   [Full Text] [Related]  

  • 38. Elimination kinetic of high polar metabolites pool of quinidine from human serum.
    Camsonne R; Moulin MA; Charbonneau P; Bazin C
    Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):74-5. PubMed ID: 3988396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accumulation of 3-hydroxyquinidine following chronic quinidine therapy.
    Ackerman BH; Olsen KM; Pappas AA
    DICP; 1991; 25(7-8):867-9. PubMed ID: 1949948
    [No Abstract]   [Full Text] [Related]  

  • 40. Total and unbound concentrations of quinidine and 3-hydroxyquinidine at steady state.
    Wooding-Scott RA; Visco J; Slaughter RL
    Am Heart J; 1987 Feb; 113(2 Pt 1):302-6. PubMed ID: 3812182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.